Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03902210
Other study ID # STUDY00009352
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 25, 2019
Est. completion date March 25, 2020

Study information

Verified date March 2020
Source Arizona State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Specific aim #1: Assess feasibility (i.e., acceptability, practicality, demand, limited efficacy) of a home-based, online yoga intervention in patients following allogeneic stem cell transplant. Feasibility benchmarks will include: >70% satisfied with the intervention and >70% intending to continue participating in online yoga (i.e., acceptability); >70% of participants achieving an average of >42 min/week (70% of presceibed 60 min/week) of online yoga throughout the 12-week intervention (i.e., demand); >70% completing questionnaires across all four time points (i.e., practicality); at least small effect sizes of the intervention on physical function, fatigue, anxiety, sleep disturbance, social functioning, pain interference, depression, and quality of life as compared to a podcast control group (i.e., limited efficacy).


Description:

Online Yoga Group: The intervention will be 12-weeks in duration and will consist of a series of pre-approved online yoga classes (6 manufactured specifically for the cancer-afflicted patients instructed by Udaya yoga therapist, Jules Mitchell, MS). Patients will be asked to complete a minimum of 60 minutes per week of yoga practice with encouragement to do more if they can. All Udaya.com videos will include a proper warm-up, cool down, and closing mindfulness activity (i.e., message from yoga therapist, brief meditation, final relaxation). Qualified Udaya yoga instructors who collectively have over 200 years of training and experience will expertly instruct the online yoga classes. Participants will be instructed to view a safety handout (see yoga safety & modifications handout) before gaining access to the Udaya video library. Yoga therapist, Jules Mitchell and PIs Huberty and Palmer will pre-approve Udaya videos that are appropriate for this population.

A 12-week yoga prescription utilized in previous online yoga studies in MPN patients will be used in the proposed study for BMT patients. The 12-week yoga prescription was designed to be safe and progressive for cancer patients. During the intervention, all classes will offer alternative poses, modifications, and use of props (i.e., yoga blocks and straps) in the instance poses are difficult for the participant (i.e., painful, irregular, uneven breath) and to ensure safety. In addition to specific instruction regarding form and safety, the yoga therapist will provide descriptions of each video that includes tips and modifications to poses (e.g., set the knee on your yoga mat if this feels more comfortable for you). Additionally, patients will also receive a yoga modifications handout outlining the contraindicated yoga poses with modifications (see yoga safety & modifications handout). This handout will include an exercise warning for patients that experience dizziness, lightheadedness or faintness, excessive shortness of breath, chest pain, and that they need to stop the activity and contact their health care professional immediately if these symptoms are experienced.

The participants will access their yoga prescription on the Udaya.com website using their provided username and password (see instruction document). Participants will be asked to participate in a total of at least 60 minutes of yoga and keep a log of their participation utilizing a daily log available through a REDCap link (see yoga group weekly log). For the entire study, participants will record in their log each time they participate in yoga, the class in which they participated, how long they practiced (start and stop time), their perceived exertion, and their perceived mindfulness. Research staff will provide a weekly reminder email at the beginning of each week encouraging participation in their weekly yoga (see weekly reminder emails). We will ask that participants follow the yoga prescription, but if participants feel they want to deviate from the prescription they have the option to participate in any videos assigned in previous weeks or in any of the additional videos included each week in the prescription.

Podcast Control Group: The podcast control group will be asked to view 60 minutes per week of online podcast videos. The podcast videos will contain general cancer-related health education material. To match the online yoga group for time and attention, 60 minutes per week will be prescribed, however, participants will have the ability to view additional videos each week. Furthermore, participants will also track their podcast video viewing each week in a daily log (see podcast group weekly log) by recording each time they view a video, the video that they viewed, and how long they viewed the video.


Recruitment information / eligibility

Status Completed
Enrollment 41
Est. completion date March 25, 2020
Est. primary completion date March 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 1) have received a bone marrow transplant 6 months ago

- 2) have a cancer diagnosis

- 3) no active infections

- 4) platelet count >50

- 5) answer "no" to all items on the Physical Activity Readiness Questionnaire (PAR-Q), or be willing to obtain a signed medical release from their physician in the case that a question is answered with a "yes"

- 6) have access to a desktop or laptop on a regular basis

- 7) have access to reliable internet

- 8) read and understand English

- 9) age 18 years or older

- 10) willing to be randomized to one of two groups

Exclusion Criteria:

- 1) Engagement in yoga in the past year

- 2) currently engage in =150 min/week of moderate-/vigorous-intensity physical activity on a weekly basis

- 3) have a history of syncope in last 2 months

- 4) have a history of recurrent falls (=2 in 2 months)

- 5) Any planned change in pharmacologic intervention (i.e., new drug) during the study interval (i.e., 20 weeks)

- 6) have an Eastern Cooperative Oncology Group 3 (ECOG 3) questionnaire score greater than three

- 7) currently utilize Udaya.com

- 8) currently pregnant

- 9) currently reside outside of the United States of America

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Online Yoga
60 minutes per week of online yoga through Udaya.com
Podcast
60 minutes per week of podcasts

Locations

Country Name City State
United States Arizona State University Phoenix Arizona

Sponsors (2)

Lead Sponsor Collaborator
Arizona State University Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Physical Function This measure is captured through the PROMIS-29 Physical Function Subscale. Raw scores can range from 4-20, with higher scores indicating better physical function. Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20)
Primary Anxiety This measure is captured through the PROMIS-29 Anxiety Subscale. Raw scores range from 4-20, with higher scores indicating more anxiety. Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20)
Primary Depression This measure is captured through the PROMIS-29 Depression Subscale. Raw scores range from 4-20, with higher scores indicating more depression. Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20)
Primary Fatigue This measure is captured through the PROMIS-29 Fatigue Subscale. Raw scores range from 4-20, with higher scores indicating more fatigue. Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20)
Primary Sleep Disturbance This measure is captured through the PROMIS-29 Sleep Disturbance Subscale. Raw scores range from 4-20, with higher scores indicating more sleep disturbance. Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20)
Primary Ability to Participate in Social Roles and Activities This measure is captured through the PROMIS-29 Ability to Participate in Social Roles and Activities Subscale. Raw scores range from 4-20, with higher scores indicating a better ability to participate in social roles and activities. Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20)
Primary Pain Interference This measure is captured through the PROMIS-29 Pain Interference Subscale. Raw scores range from 4-20, with higher scores indicating more interference of pain in daily life. Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20)
Primary Pain Intensity This measure is captured through the PROMIS-29 Pain Intensity Subscale. This is a single-item question asking the participant to rate their average level of pain on a 0-10 scale, with a higher score indicating worse pain. Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20)
Primary Physical Health This measure is captured through the PROMIS Global Health Physical Subscale. Raw scores range from 2-10, with higher scores indicating better physical health. Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20)
Primary Chronic Graft vs. Host Disease Symptoms This measure is captured with the Lee Symptom Score, which assesses various symptoms commonly associated with Graft vs. Host Disease. Raw scores range from 0-120, with higher scores indicating higher symptom burden. Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20)
Primary Mental Health This measure is captured through the PROMIS Global Health Mental Health Subscale. Raw scores range from 2-10, with higher scores indicating better mental health. Change from baseline to midpoint (week 6), post-intervention (week 12), and follow-up (week 20)
Secondary Objective Physical Activity Objective physical activity will be collected with the Fitbit Flex 2 device. This device captures light, moderate, and vigorous-intensity activity via an accelerometer. Daily physical activity throughout the 12-week intervention (baseline through week 12)
Secondary Subjective Physical Activity Subjective physical activity will be assessed with the Modifiable Activity Questionnaire. This questionnaire asks participants to indicate the days and the durations in which they participated in 39 different activities. Weekly minutes of activity is calculated from the information provided. Weekly physical activity throughout the 12-week intervention (baseline through week 12)
Secondary Objective Yoga/Podcast Participation Participation in yoga or podcasts is collected through the number of minutes spent viewing/watching/listening to the yoga videos and podcast sessions. Weekly throughout the 12-week intervention (baseline through week 12)
Secondary Subjective Yoga/Podcast Participation Participation in yoga or podcasts is collected through self-report yoga or podcast logs. Weekly throughout the 12-week intervention (baseline through week 12)
See also
  Status Clinical Trial Phase
Withdrawn NCT02451462 - Pilot Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients N/A
Completed NCT03654599 - Effects of Digital Stories Intervention on Psychosocial Well-being N/A
Active, not recruiting NCT04395222 - Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation Phase 2
Not yet recruiting NCT05603156 - A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive N/A
Completed NCT03530969 - Geriatric Communication Skills Training Program for Oncology Clinicians N/A
Recruiting NCT04115241 - Activity Levels in Bone Marrow Transplant Patients
Completed NCT00143780 - Pneumonia Vaccine in Bone Marrow Transplant Recipients: Usefulness of Donor Vaccination Phase 4
Completed NCT05662631 - Remote Monitoring and Home-based Health Care for Treatment of Bone Marrow Transplant Patients N/A
Completed NCT03028961 - Stanford Letter or Traditional Advance Directive in Advance Care Planning in Patients Undergoing Bone Marrow Transplant N/A
Completed NCT02575079 - Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT N/A
Active, not recruiting NCT02665065 - Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia Phase 3
Completed NCT01735565 - Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplant N/A
Completed NCT04041219 - Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients Phase 4
Not yet recruiting NCT06361173 - Spanish BMT4me Usability & Acceptability
Completed NCT03030248 - Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients Phase 2
Completed NCT00695123 - Screening for Subjects to Participate in Studies of Blood Disorders
Terminated NCT02057289 - A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis Phase 1
Completed NCT04275830 - The Effects of Heart Rate Variability Biofeedback Training on Hematopoietic Cell Transplantation Patients N/A
Completed NCT03245788 - Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study N/A
Completed NCT03758911 - Perspectives on Bone Marrow Donors Who Donate for Their Parent